慢性乙型肝炎抗病毒治疗Treat all时代离我们还有多远？

丁洋; 窦晓光

doi:10.3969/j.issn.1001-5256.2021.11.011

慢性乙型肝炎抗病毒治疗Treat all时代离我们还有多远？

DOI: 10.3969/j.issn.1001-5256.2021.11.011

丁洋,
窦晓光^,

中国医科大学附属盛京医院感染科，沈阳 110022

详细信息

通信作者:
窦晓光，guang40@163.com

中图分类号: R512.62
计量
- 文章访问数: 406
- HTML全文浏览量: 74
- PDF下载量: 99
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-14
- 录用日期: 2021-09-14
- 出版日期: 2021-11-20

How far are we from the "Treat all" era of antiviral therapy for chronic hepatitis B

Yang DING,
Xiaoguang DOU^,

Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang 110022, China

摘要

- 乙型肝炎病毒 /
- 乙型肝炎，慢性 /
- 不确定期 /
- 治疗学
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Indeterminate Phrase /
- Therapeutics

HTML全文

参考文献(9)

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	CORNBERG M, SANDMANN L, PROTZER U, et al. S3-Leitlinie der deutschen gesellschaft für gastroenterologie, verdauungs-und stoffwechselkrankheiten (DGVS) zur prophylaxe, diagnostik und therapie der hepatitis-B-virusinfektion-(AWMF-Register-Nr. 021-11)[J]. Z Gastroenterol, 2021, 59(7): 691-776. DOI: 10.1055/a-1498-2512.
[3]	CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311.
[4]	GUI HL, WANG H, YANG YH, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase[J]. J Viral Hepat, 2010, 17(Suppl 1): 44-50. DOI: 10.1111/j.1365-2893.2010.01270.x.
[5]	KIM JH, SINN DH, KANG W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343. DOI: 10.1002/hep.28916.
[6]	FAN YX, DOU XG. Optimal timing significance and clinical implications for the treatment of chronic HBV-infected patients with normal ALT[J]. Chin J Hepatol, 2020, 28(11): 170-172. DOI: 10.3760/cma.j.cn501113-20201026-00579. 樊耀昕, 窦晓光. ALT正常的慢性HBV感染者疾病评估及治疗时机选择[J]. 中华肝脏病杂志, 2020, 28(11): 170-172. DOI: 10.3760/cma.j.cn501113-20201026-00579.
[7]	CHU CM, LIAW YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus[J]. Am J Gastroenterol, 2009, 104(7): 1693-1699. DOI: 10.1038/ajg.2009.187.
[8]	HAN C, DOU XG. Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: Consensus and contention[J]. Chin J Hepatol, 2021, 4(29): 192-195. DOI: 10.3760/cma.j.cn501113-20210326-00139. 韩超, 窦晓光. 口服NAs抗病毒治疗降低HBV相关肝细胞癌: 共识与争鸣[J]. 中华肝脏病杂志, 2021, 4(29): 192-195. DOI: 10.3760/cma.j.cn501113-20210326-00139.
[9]	FANNING GC, ZOULIM F, HOU J, et al. Therapeutic strategies for hepatitis B virus infection: Towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11): 827-844. DOI: 10.1038/s41573-019-0037-0.